1. 305PExposure-efficacy progression-free survival (PFS) analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in the phase III EMBRACA trial. (23rd October 2018) Authors: Yu, Y; Elmeliegy, M; Litton, J K; Tudor, I C; Czibere, A; Zheng, J; Wang, D D Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 306PExposure-safety analyses in breast cancer patients with germline BRCA1/2 mutations receiving talazoparib (TALA) in EMBRACA and ABRAZO trials. (23rd October 2018) Authors: Elmeliegy, M; Yu, Y; Litton, J K; Turner, N C; Czibere, A; Wilson, G G; Tudor, I C; Zheng, J; Wang, D D Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 859TiPTALAPRO-1: An open-label, response rate phase II study of talazoparib (TALA) in men with DNA damage repair defects (DDR) and metastatic castration-resistant prostate cancer (mCRPC) who previously received taxane-based chemotherapy (CT) and progressed on ≥ 1 novel hormonal therapy (NHT). (23rd October 2018) Authors: de Bono, J S; Higano, C; Saad, F; Miller, K; Casey, M; Czibere, A; Healy, C; Fizazi, K Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗